ID: ALA349947

Max Phase: Preclinical

Molecular Formula: C30H26N4O4

Molecular Weight: 506.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(-c2cnc(N3CCc4c([nH]c5ccccc45)C3c3ccc4c(c3)OCO4)nc2)cc1OC

Standard InChI:  InChI=1S/C30H26N4O4/c1-35-24-9-7-18(13-26(24)36-2)20-15-31-30(32-16-20)34-12-11-22-21-5-3-4-6-23(21)33-28(22)29(34)19-8-10-25-27(14-19)38-17-37-25/h3-10,13-16,29,33H,11-12,17H2,1-2H3

Standard InChI Key:  DQBJCYDEYXHIFJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 506.56

Molecular Weight (Monoisotopic): 506.1954

AlogP: 5.52

#Rotatable Bonds: 5

Polar Surface Area: 81.73

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 2.63

CX LogP: 5.36

CX LogD: 5.36

Aromatic Rings: 5

Heavy Atoms: 38

QED Weighted: 0.34

Np Likeness Score: -0.23

References

1. Sui Z, Guan J, Macielag MJ, Jiang W, Qiu Y, Kraft P, Bhattacharjee S, John TM, Craig E, Haynes-Johnson D, Clancy J..  (2003)  Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.,  13  (4): [PMID:12639576] [10.1016/s0960-894x(02)01036-3]

2. Sui Z, Guan J, Macielag MJ, Jiang W, Qiu Y, Kraft P, Bhattacharjee S, John TM, Craig E, Haynes-Johnson D, Clancy J..  (2003)  Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.,  13  (4): [PMID:12639576] [10.1016/s0960-894x(02)01036-3]

3. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source

Source(1):

• Scientific Literature